New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2013
11:53 EDTHNZ, GNC, OMX, SPLS, INFIHigh option volume stocks: HNZ GNC OMX SPLS INFI
News For HNZ;GNC;OMX;SPLS;INFI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 21, 2014
09:12 EDTGNCGNC, eBay, Vivendi recommended as long ideas by Sandler, Bloomberg reports
Subscribe for More Information
06:22 EDTSPLSStaples may be latest retailer to be hacked, Krebs reports
Subscribe for More Information
October 20, 2014
14:46 EDTGNCVitamin Shoppe may hire adviser amid pressure for deal, Reuters says
Vitamin Shoppe (VSI), which has been urged by activist shareholders to consider a sale, is speaking to banks and may hire a financial adviser, according to Reuters, citing people familiar with the matter. Note that Reuters previously reported on September 18 that some large Vitamin Shoppe holders have urged the company to consider a sale to rival GNC Holdings (GNC) or to a private equity buyer. That same day, The Financial Times reported that GNC was considering a possible sale after receiving attention from private equity suitors. Following this latest report from Reuters, shares of Vitamin Shoppe are up 6.7% to $45.23 in afternoon trading, while GNC shares are up over 3% to $38.88. Reference Link
10:24 EDTSPLSStaples and Cynthia Rowley announce exclusive collaboration
Staples and designer Cynthia Rowley announce an exclusive work and home office collection that incorporates designs into everyday work and home spaces. Beginning mid-November, Staples stores nationwide will debut the exclusive Cynthia Rowley Collection.
07:04 EDTINFIInfinity Pharmaceuticals coverage resumed with a Hold at Stifel
October 16, 2014
07:41 EDTINFIInfinity reports duvelisib Phase 2a primary endpoint not met
Infinity Pharmaceuticals announced encouraging topline data from its Phase 2a exploratory study of duvelisib, or IPI-145. Data from this randomized, double-blind, placebo-controlled, cross-over study demonstrated that duvelisib was well tolerated and met several secondary and exploratory endpoints in an allergen challenge study. Clinical improvement was observed in the late-phase asthmatic response FEV1 among patients who received duvelisib administered at the highest dose tested, 25 mg twice daily for five days, however the primary endpoint of the study was not met as it did not reach statistical significance. Multiple secondary clinical endpoints measuring improvements in lung function following duvelisib administration were achieved with statistical significance and were associated with changes in key cytokines and chemokines involved in the asthmatic response. Taken together, these data demonstrate early proof-of-activity in this allergen challenge study. Infinity expects to present the final data in a peer-reviewed setting after all analyses are complete. In addition, the company anticipates determining its next steps for development of PI3K-delta,gamma inhibitors in inflammation after evaluating the results from the ASPIRA study in rheumatoid arthritis, which are expected by the end of 2014.
October 13, 2014
13:05 EDTINFIInfinity Pharmaceuticals management to meet with ISI Group
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use